Cysal Receives Seven Figure Seed Financing

Cysal GmbH, a Münster, Germany-based biotechnology company, has received a seven-figure seed financing.

Backers include eCAPITAL entrepreneurial Partners AG‘s Gründerfonds Münsterland and High-Tech Gründerfonds II.

The company intends to use the capital to accelerate business development, set up bio-technological mass production of dipeptides and launch the first finished products on the market.

Established in 2012 as a spin-off from the Institute for Molecular Microbiology and Biotechnology at the Westphalian Wilhelms-University in Münster, Cysal leverages its patented biotechnological manufacturing process to produce arginineaspartate and lysine-aspartate dipeptides on an industrial scale. The company uses these dipeptides, a combination of two amino acids, as the base material for the manufacture of finished products developed in-house such as energy tonics, skin creams, fish feed additives, and infusions.



Join the discussion